Filtered By:
Condition: Heart Attack
Countries: Spain Health
This page shows you your search results in order of date. This is page number 9.
Order by Relevance | Date
Total 127 results found since Jan 2013.
Urine Arsenic and Arsenic Metabolites in U.S. Adults and Biomarkers of Inflammation, Oxidative Stress, and Endothelial Dysfunction: A Cross-Sectional Study
Conclusion:
In a cross-sectional study of U.S. adults, we observed some positive associations of uAs and toenail As concentrations with biomarkers potentially relevant to CVD pathogenesis and inflammation, and evidence of a higher capacity to metabolize inorganic As was negatively associated with a marker of oxidative stress. https://doi.org/10.1289/EHP2062
Received: 14 April 2017
Revised: 13 November 2017
Accepted: 15 November 2017
Published: 15 December 2017
Address correspondence to S.F. Farzan, 2001 N. Soto St., Los Angeles, CA, 90032. Telephone: (323)-442-5101; Email: sffarzan@usc.edu
Supplemental Material is ava...
Source: EHP Research - December 16, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research
Patient Preferences for Attributes of Type 2 Diabetes Mellitus Medications in Germany and Spain: An Online Discrete-Choice Experiment Survey
ConclusionsRespondents in Germany and Spain were willing to trade efficacy for improvements in side effects and mode of administration. Given the variety of T2DM medications currently available, the results suggest that careful discussion about patient preferences could help improve patient satisfaction with T2DM treatment.
Source: Diabetes Therapy - November 3, 2017 Category: Endocrinology Source Type: research
Plasma Metal Concentrations and Incident Coronary Heart Disease in Chinese Adults: The Dongfeng-Tongji Cohort
Conclusions:
Our study suggested that incident CHD was positively associated with plasma levels of titanium and arsenic, and inversely associated with selenium. Additional research is needed to confirm these findings in other populations. https://doi.org/10.1289/EHP1521
Received: 22 December 2016
Revised: 17 September 2017
Accepted: 19 September 2017
Published: 19 October 2017
Address correspondence to T. Wu, or A. Pan, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hongkong Rd., Wuhan 430030, Hubei, China. Telephone: +86-27-83692347. Email: wut@mails.tjmu.edu.cn or p...
Source: EHP Research - October 20, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Research Source Type: research
Diabetes News
Abstract
More than 31,000 attendeesfrom around the world gathered in Barcelona, Spain for the 2017 European Society of Cardiology conference. In presentinga post‐hoc analysis of the Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes(LEADER)1 trial, Dr Neil Poulter (Imperial College London, UK) showedthat results are still positive, indicating cardioprotection, after adjusting for baseline history of stroke or myocardial infarction (MI), which had no mediating effect on the significant association between Novo Nordisk's (Copenhagen, Denmark) glucagon‐like peptide‐1 (GLP‐1) agonist Victoza (liraglutide) and c...
Source: Journal of Diabetes - September 1, 2017 Category: Endocrinology Authors: Ann M. Carracher, Payal H. Marathe, Kelly L. Close Tags: News Source Type: research
Results of global fats and carbs study not very relevant for UK
Conclusion
The results of the study have been presented in the media as if they overturn all current dietary guidelines. In the UK at least, that is completely misleading. The study results support the UK guidelines, having found that people who get around 50% of their calories from carbohydrates and 35% from fat, as recommended by Public Health England, were likely to live the longest.
There are some limitations to the study, not least that observational studies cannot prove cause and effect.
For example, the very low fat and high carbohydrate levels of diets found among some participants in the study might simply repres...
Source: NHS News Feed - August 30, 2017 Category: Consumer Health News Tags: Food/diet Source Type: news
Victoza ® reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events
A new analysis of the landmark LEADER trial shows that Victoza® (liraglutide) reduced the risk of major cardiovascular (CV) events in people with type 2 diabetes at high CV risk, irrespective of their history of having a heart attack and/or stroke or not having any of these events, when compared to placebo.(1) This post-hoc analysis was presented today at the European Society of Cardiology (ESC) Annual Congress in Barcelona, Spain.
Source: World Pharma News - August 28, 2017 Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts
Abstract: To analyze in several immune-mediated inflammatory diseases (IMIDs) the influence of demographic and clinical-related variables on the prevalence of cardiovascular disease (CVD), and compare their standardized prevalences.
Cross-sectional study, including consecutive patients diagnosed with rheumatoid arthritis, psoriatic arthritis, psoriasis, systemic lupus erythematosus, Crohn disease, or ulcerative colitis, from rheumatology, gastroenterology, and dermatology tertiary care outpatient clinics located throughout Spain, between 2007 and 2010. Our main outcome was defined as previous diagnosis of angina, myocardi...
Source: Medicine - June 1, 2017 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
